Diabetes

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

19 марта 2026 Сообщено ИИ Проверено фактами

A randomized controlled trial in 180 adults found that prescribing diets high, regular or low in sweet-tasting foods for six months did not change participants’ liking for sweet taste, body weight, energy intake, or several biomarkers linked to diabetes and cardiovascular disease. The researchers concluded the results do not support public health advice that aims to reduce exposure to sweet-tasting foods regardless of whether sweetness comes from sugar, low-calorie sweeteners, fruit or dairy.

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

4 февраля 2026 Сообщено ИИ

A new study from Johns Hopkins Medicine reveals that sex hormones like testosterone and estradiol influence heart disease risk in type 2 diabetes differently for men and women. In men, higher testosterone levels were linked to lower risk, while rising estradiol was associated with higher risk; no such patterns emerged in women. The findings suggest potential for more personalized prevention strategies.

A large UK study indicates that statins lower death and heart event risks for adults with type 2 diabetes, regardless of their predicted cardiovascular risk. Benefits appeared even among low-risk individuals, questioning current prescribing guidelines. Side effects remained minimal.

15 января 2026 Сообщено ИИ

An international team of researchers has identified a previously unknown type of diabetes in newborns caused by mutations in the TMEM167A gene. This rare condition leads to both high blood sugar and neurological issues like epilepsy and microcephaly. The findings, published in a leading medical journal, could enhance understanding of insulin production in broader diabetes research.